Loss of intrahepatic <scp>HB</scp>s<scp>A</scp>g expression predicts sustained response to peginterferon and is reflected by pronounced serum <scp>HB</scp>s<scp>A</scp>g decline

Arends, Pauline; Rijckborst, Vincent; Zondervan, Pieter E.; Buster, Erik H.C.J.; Çakalǒglu, Yılmaz; Ferenci, Péter; Tabak, Fehmı; Akarca, Ulus Salih; Simon, Krzysztof; Sonneveld, Milan J.; Hansen, Bettina E.; Janssen, Harry L.A.

doi:10.1111/jvh.12218

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, 60 IHCs were treated with IFN for 96 weeks, of which 39 patents achieved HBsAg clearance. During treatment, ALT and AST in the NR and R groups were increased, especially in HBsAg clearance group, which was similar to previous reports, suggesting that patients with good response to interferon therapy often experienced elevated ALT (15,16). After treatment with PEG-IFN, the quantity of HBsAg at 12 weeks and 24 weeks was significantly lower than baseline, especially in the R group, suggesting that patients with rapidly declining HBsAg in the treatment had a higher incidence of HBsAg clearance (17).…”

Section: Discussionsupporting

confidence: 90%

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers

Lin

Liu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

PurposeOur recent study showed a high rate of HBsAg clearance in inactive HBsAg carriers (IHCs) treated with pegylated IFN (PEG-IFN). To better understand the immune-mediated component of HBsAg clearance, this study investigated the role of serum immunoglobulin G (IgG) and its subclasses in predicting HBsAg clearance in IHCs with PEG-IFN therapy.MethodsIn this study, IHCs received PEG-IFN for 96 weeks. Subjects who achieved clearance of HBsAg were considered responders (R group), and those in whom HBsAg was not cleared were considered non-responders (NR group). The HBsAg, ALT, and serum lgG subtypes (lgG1, IgG2, IgG3, lgG4) were tested at baseline, and at 12 and 24 weeks of treatment. To evaluate the factors in predicting HBsAg clearance, univariate and multivariate logistic regression analyses were performed. The receiver operator characteristic curves and the area under the receiver operator characteristic curve (AUROC) were used to evaluate prognostic values.ResultsOur results showed that 39 cases obtained HBsAg clearance (group R), while 21 cases did not (group NR). There was no significant difference in age, ALT, and AST levels between the two groups. The serum levels of IgG1, lgG2, lgG3 and lgG4 at baseline, and at 12 and 24 weeks were significantly lower in IHC with HBsAg clearance than in the NR group. Univariate logistic regression analysis showed that serum IgG1, IgG2, IgG3, and IgG4 levels at baseline, and at 12, and 24 weeks were all strong predictors of HBsAg clearance. In all indicators, lgG2 had the highest AUROC at baseline and lgG3 the highest AUROC at week 12. A multifactor logistic analysis was performed with y=33.933-0.001*BaselinelgG1-0.002*BaselinelgG2. The area under the curve was 0.941 with 100% sensitivity and 76.19% specificity.ConclusionTogether, our findings suggest that serum IgG has a higher predictive value compared to the convention predictors of HBsAg and ALT for HBsAg clearance and thus may be a better clinical predictor of HBsAg clearance in IHCs.

show abstract

Section: Discussionsupporting

confidence: 90%

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers

Lin

Liu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that the change of serum HBsAg levels during PegIFN therapy mimics the change of both intrahepatic cccDNA and intrahepatic HBsAg, suggesting that a decline in serum HBsAg levels is associated with the induction of an effective anti-HBV immune response [2,[56][57][58]. Therefore, HBsAg levels are a valuable tool for the monitoring of patients treated with PegIFN.…”

Section: Pegylated Interferon Alfa Therapymentioning

confidence: 99%

The role of quantitative hepatitis B surface antigen revisited

Cornberg

Wong

Locarnini

et al. 2017

Journal of Hepatology

302

301

View full text Add to dashboard Cite

“…During pegylated‐interferon therapy, a decline in serum HBsAg levels is associated with the induction of an effective anti‐HBV immune response, and it may be a useful marker for predicting the viral response and hepatitis B early antigen (HBeAg) seroconversion . HBsAg seroclearance and safe discontinuation during long‐term nucleos(t)ide analogue therapy may also be associated with the baseline HBsAg levels …”

Section: Introductionmentioning

confidence: 99%

Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China

Zhang

Tong³

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The kinetics of serum hepatitis B surface antigen (HBsAg) during the natural history of hepatitis B virus (HBV) infection has been studied, but the factors affecting them remain unclear. We aimed to investigate the factors affecting HBsAg titres, using data from multicentre, large-sized clinical trials in China. The baseline data of 1795 patients in 3 multicentre trials were studied, and the patients were classified into 3 groups: hepatitis B early antigen (HBeAg)-positive chronic HBV infection (n = 588), HBeAg-positive chronic hepatitis B (n = 596), and HBeAg-negative chronic hepatitis B (n = 611). HBsAg titres in the different phases were compared, and multiple linear progression analyses were performed to investigate the implicated factors. HBsAg titres varied significantly in different phases (P = .000), with the highest (4.60 log10 IU/mL [10%-90% confidence interval: 3.52 log10 IU/mL-4.99 log10 IU/mL]) in patients with HBeAg-positive chronic HBV infection. In all phases, age and HBV DNA were correlated with serum HBsAg level. In HBeAg-positive chronic hepatitis B patients, a negative correlation between HBsAg titres and fibrosis stage was observed. Alanine amonitransferase or necroinflammatory activity was also correlated with HBsAg titres in HBeAg-negative chronic hepatitis B patients. In conclusion, decreased HBsAg titres may be associated with advancing fibrosis in HBeAg-positive chronic hepatitis B patients or increased necroinflammation in those with HBeAg-negative chronic hepatitis B. Our findings may help clinicians better understand the kinetics of HBsAg and provide useful insights into the management of this disease.

show abstract

Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline

Cited by 7 publications

References 27 publications

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers

The role of quantitative hepatitis B surface antigen revisited

Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China

Contact Info

Product

Resources

About